

Tufia C Haddad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1545658/publications.pdf>

Version: 2024-02-01

42
papers

1,093
citations

393982

19
h-index

433756

31
g-index

44
all docs

44
docs citations

44
times ranked

1896
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293. | 0.8 | 88 |
| 2 | Aurora-A Kinase as a Promising Therapeutic Target in Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 295. | 1.3 | 76 |
| 3 | A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832. | 3.2 | 66 |
| 4 | Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418. | 0.8 | 64 |
| 5 | NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , 2018, 20, 105. | 2.2 | 58 |
| 6 | Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up. <i>Physical Therapy</i> , 2018, 98, 518-527. | 1.1 | 48 |
| 7 | Landscape of Neoadjuvant Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1408-1415. | 0.7 | 47 |
| 8 | Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19. <i>Npj Digital Medicine</i> , 2021, 4, 123. | 5.7 | 42 |
| 9 | A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1221-1227. | 1.1 | 39 |
| 10 | Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 794-807. | 1.4 | 39 |
| 11 | Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 842-851. | 1.8 | 36 |
| 12 | Aurora-A kinase oncogenic signaling mediates TGF- β -induced triple-negative breast cancer plasticity and chemoresistance. <i>Oncogene</i> , 2021, 40, 2509-2523. | 2.6 | 34 |
| 13 | Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. <i>Cancer</i> , 2016, 122, 378-385. | 2.0 | 31 |
| 14 | MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Academic Radiology</i> , 2022, 29, S145-S154. | 1.3 | 31 |
| 15 | Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ER α Expression in Initially ER α + Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e96995. | 1.1 | 30 |
| 16 | Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval. <i>JMIR Cancer</i> , 2018, 4, e10. | 0.9 | 27 |
| 17 | Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 173-182. | 0.5 | 26 |
| 18 | Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor α -Positive/Human Epidermal Growth Factor Receptor 2 α -Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458. | 0.8 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 91803-91816. | 0.8 | 23 |
| 20 | Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study. <i>JMIR Medical Informatics</i> , 2021, 9, e27767. | 1.3 | 23 |
| 21 | Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 639-647. | 1.1 | 21 |
| 22 | Managing Patients in the COVID-19 Pandemic. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 118-126. | 1.2 | 20 |
| 23 | Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005984. | 0.9 | 18 |
| 24 | Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. <i>JCO Oncology Practice</i> , 2021, 17, e1293-e1302. | 1.4 | 18 |
| 25 | Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor β . <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996. | 3.2 | 17 |
| 26 | Clinical performance pilot using cognitive computing for clinical trial matching at Mayo Clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18598-e18598. | 0.8 | 17 |
| 27 | A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544. | 1.1 | 16 |
| 28 | New-Onset Heart Failure in Association With Severe Hypertension During Trastuzumab Therapy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1734-1739. | 1.4 | 13 |
| 29 | A Scalable Framework for Telehealth: The Mayo Clinic Center for Connected Care Response to the COVID-19 Pandemic. <i>Telemedicine Reports</i> , 2021, 2, 78-87. | 0.5 | 13 |
| 30 | Novel approaches to support breast cancer survivorship care models. <i>Breast</i> , 2017, 36, 1-13. | 0.9 | 11 |
| 31 | Pilot implementation to assess the feasibility and care team impact of an app-based interactive care plan to remotely monitor breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 13-23. | 1.5 | 10 |
| 32 | Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 515-525. | 1.1 | 9 |
| 33 | Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103093. | 2.0 | 9 |
| 34 | Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3329-3338. | 3.2 | 8 |
| 35 | Avoiding the "Faux Equalizer". <i>Mayo Clinic Proceedings</i> , 2021, 96, 2963-2965. | 1.4 | 7 |
| 36 | Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 18. | 0.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. <i>Case Reports in Oncology</i> , 2016, 9, 33-38. | 0.3 | 6 |
| 38 | Aurora-A overexpression is linked to development of aggressive teratomas derived from humans iPS cells. <i>Oncology Reports</i> , 2018, 39, 1725-1730. | 1.2 | 5 |
| 39 | Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2021, 188, 477-487. | 1.1 | 5 |
| 40 | Five-Year Cumulative Incidence of Axillary Web Syndrome and Comparison in Upper Extremity Movement, Function, Pain, and Lymphedema in Survivors of Breast Cancer With and Without Axillary Web Syndrome. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 1798-1806. | 0.5 | 5 |
| 41 | Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568. | 0.6 | 4 |
| 42 | Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. <i>Clinical Breast Cancer</i> , 2018, 18, e513-e520. | 1.1 | 1 |